The primary objective of this study is to demonstrate the efficacy of 8-week treatment with Glecaprevir/Pibrentasvir in patients with confirmed acute HCV infection. Glecaprevir/Pibrentasvir is an approved drug for the treatment of chronic HCV.

Please use this link for further information:

clinicaltrials.gov